Algernon Announces Filing of U.S. FDA Pre-Ind Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use (BioSpace)

Algernon Announces Filing of U.S. FDA Pre-Ind Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use

UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, announced that it has filed its pre-IND (Investigational New Drug) meeting request with the U.S. FDA. This initiates formal communications with the U.S. FDA regarding the development of the company’s repurposed drug NP-120 (Ifenprodil) for the treatment and prevention of acute lung injury (ALI) and acute respiratory distress syndrome associated with COVID-19 (coronavirus) infection. The request for a pre-IND meeting was accompanied by the complete pre-IND briefing document.

Learn more about Algernon Announces Filing of U.S. FDA Pre-Ind Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use.
Related news Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus.
X